Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kielce
Clinical trial register · Poland

Clinical Trials in Kielce, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC15 AstraZeneca12 Janssen Research & Development, LLC11 Novartis Pharmaceuticals6 Hoffmann-La Roche6
Site location
Warsaw1315 Krakow882 Poznan705 Gdansk657 Lodz619
All 264 locations
Target enrolment
to

Trials with a site in Kielce

116 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Hoffmann-La Roche
Phase 3
400
Bystra, Gda?sk, Kielce
2026-10-06
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
2026-09-24
Recruiting
Jan Kochanowski University
Observational
200
Kielce
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Bydgoszcz, Katowice, Kielce, Krakow, Ossy, Warsaw
2026-08-31
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Bydgoszcz, Elblag, Katowice, Kielce, Krakow, Kłodzko, Lodz, Lublin
2026-08-28
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Częstochowa, Kielce, Krakow, Lodz, Poznan, Radom, Warsaw
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
Anatomical and Imaging Assessment of the Alveolar Antral Artery Canal Using CBCT
NCT07726121Maxillary Sinus, Cone-Beam Computed Tomography, Artery
Hospital of the Ministry of Interior, Kielce, Poland
Observational
1,000
Kielce
2026-07-01
Recruiting
AstraZeneca
Phase 3
4,500
Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
2026-06-26
Recruiting
Novo Nordisk A/S
Phase 2
300
Lublin, Bialystok, Kielce, Oświęcim
2026-06-22
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan
2026-05-28
Recruiting
BeOne Medicines
Phase 3
1,056
Bialystok, Gdynia, Kielce, Krakow, Opole, Otwock, Warsaw
2026-05-22
Recruiting
TG Therapeutics, Inc.
Phase 2
350
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw
2026-04-01
Recruiting
Michał Pasierbek
Not applicable
120
Wroclaw, Lublin, Warsaw, Krakow, Gdansk, Zabrze, Olsztyn, Kielce
2026-04-01
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Chorzów, Katowice, Kielce, Krakow, Lodz, Malbork, Nowy Targ, Poznan
2026-03-26
Recruiting
Hoffmann-La Roche
Phase 2
360
Poznan, Rzeszw, Katowice, ?ory, ?ód?, Bydgoszcz, Gda?sk, Kielce
2026-03-10
Recruiting
Poland-Italy Aortic Research Bridge Real World Registry
NCT07476196Abdominal Aortic Aneurysm
American Heart of Poland
Observational
200
Bialystok, Bielsko-Biala, Bytom, Chrzanów, Ełk, Gdynia, Kielce, Krakow
2026-03-01
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Brzozów, Kielce, Krakow, Lodz, Lublin, Poznan, Torun, Wroclaw
2026-02-08
By invitation
Immunovant Sciences GmbH
Phase 2
372
Bydgoszcz, Lublin, Warsaw, Kielce
2026-01-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Warsaw, Gliwice, Siedlce, Kielce
2026-01-19
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Radom, Katowice, Kielce, Lodz, Lublin, Opole, Wroclaw, Tomaszów Mazowiecki
2026-01-06
Recruiting
Navigator Medicines, Inc.
Phase 2
150
Katowice, Kielce, Ossy, Warsaw, Wroclaw
2026-01-05
Recruiting
Large Language Models for Dental Radiology Report Generation From Structured Textual Data
NCT07676318Radiography, Oral Health, Large Language Model, Natural Language Processing (NLP)
Hospital of the Ministry of Interior, Kielce, Poland
Observational
100
Kielce
2026-01-01
Active, closed
Kailera
Phase 3
1,270
Krakow, Warsaw, Gdynia, Chorzów, Bydgoszcz, Wroclaw, Kielce
2025-12-30
Recruiting
Incyte Corporation
Phase 3
466
Bialystok, Gdansk, Kielce, Siedlce, Szczecin
2025-12-09
Recruiting
GlaxoSmithKline
Phase 3
450
Kielce, Poznan, Warsaw
2025-12-03
Recruiting
Genmab
Phase 3
660
Lublin, Siedlce, Bialystok, Szczecin, Kielce, Lodz
2025-11-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Bialystok, Gdansk, Kielce, Lodz, Malbork, Nowa Sól, Poznan, Rzeszów
2025-11-27
Recruiting
AstraZeneca
Phase 3
420
Kielce, Krakow, Lodz, Lublin, Wroclaw
2025-11-11
Recruiting
Takeda
Phase 2
200
Osielsko, Wroclaw, Szczecin, Katowice, Rzeszów, Warsaw, Lodz, Kielce
2025-11-03
Recruiting
Casper Rokx
Not applicable
5,200
Janów Lubelski, Kielce, Warsaw
2025-10-01
Recruiting
Medical University of Silesia
Observational
300
Bialystok, Katowice, Kielce, Opole, Wroclaw
2025-09-15
Recruiting
BeOne Medicines
Phase 3
500
Gdansk, Kielce, Lodz, Lublin, Olsztyn, Torun, Warsaw, Wroclaw
2025-09-04
Active, closed
Analysis of Tooth Root Number
NCT07170956Tooth Abnormalities, Tooth Abnormality, Tooth Anatomy, Tooth Development Disorder
Hospital of the Ministry of Interior, Kielce, Poland
Observational
4,000
Kielce
2025-09-01
Recruiting
GlaxoSmithKline
Phase 3
420
Gliwice, Kielce, Lodz, Olsztyn, Otwock, Poznan, Przemyśl, Siedlce
2025-08-11
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Kielce, Oświęcim, Skorzewo
2025-07-07
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Bialystok, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lodz, Lublin
2025-06-27
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Bialystok, Szczecin, Bydgoszcz, Chorzów, Kielce, Lublin, Olsztyn, Opole
2025-06-19
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bialystok, Bydgoszcz, Gdansk, Kielce, Lodz, Wroclaw
2025-06-04
Recruiting
Prevention of Postoperative Hernias in Emergency Surgery
NCT06815822Incarcerated Hernia, Appendicitis Acute, Cholecystitis, Acute, Ileus
Jan Kochanowski University
Observational
500
Kielce
2025-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Poznan, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Kielce
2025-05-22
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
14
Kielce, Warsaw
2025-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Poznan, Warsaw, Bialystok, Szczecin, Kielce
2025-04-09
Recruiting
Eli Lilly and Company
Phase 3
700
Kielce, Poznan, Szczecin
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Bialystok, Bydgoszcz, Chrzanów, Karczew, Katowice, Kielce, Krakow, Lodz
2025-03-18
Recruiting
AbbVie
Phase 1/2
252
Lublin, Bialystok, Gdansk, Kielce
2025-03-06
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Lublin, Poznan, Warsaw
2025-01-13
Recruiting
BioNTech SE
Phase 2/3
1,580
Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow
2025-01-07
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Bialystok, Kielce
2024-11-25
Recruiting
Abivax S.A.
Phase 2
212
Bydgoszcz, Kielce, Knurów, Krakow, Lodz, Nowy Targ, Opole, Piotrkow Trybunalski
2024-10-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Poznan, Krakow, Wroclaw, Warsaw, Przemyśl, Gdansk, Olsztyn, Kielce
2024-10-21
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Poznan, Gdansk, Iława, Kielce, Lodz, Lublin, Sochaczew, Wroclaw
2024-09-26
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Torun, Wałbrzych, Krakow, Gdansk, Lodz, Kielce
2024-09-16
Recruiting
AbbVie
Phase 2
590
Bydgoszcz, Torun, Krakow, Warsaw, Sopot, Tychy, Kielce
2024-09-04
Recruiting
Pomeranian Medical University Szczecin
Observational
300
Bialystok, Gdansk, Gliwice, Kielce, Krakow, Lublin, Opole, Siedlce
2024-09-02
Recruiting
Bayer
Phase 3
444
Poznan, Wroclaw, Otwock, Warsaw, Bialystok, Lodz, Kielce
2024-08-28
Active, closed
Genmab
Phase 3
379
Poznan, Krakow, Warsaw, Kielce
2024-08-13
Recruiting
Amgen
Phase 3
450
Gdynia, Kielce, Lodz, Opole, Poznan, Warsaw
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Lublin, Katowice, Kielce
2024-07-16
Active, closed
Celldex Therapeutics
Phase 3
963
Bialystok, Bydgoszcz, Elblag, Gdansk, Katowice, Kielce, Krakow, Lodz
2024-07-11
Active, closed
AstraZeneca
Phase 3
339
Katowice, Kielce, Ossy, Rzeszów, Warsaw
2024-06-29
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Biała Podlaska, Gdansk, Katowice, Kielce, Lublin, Wroclaw
2024-06-07
Active, closed
Janssen Research & Development, LLC
Phase 2
333
Biała Podlaska, Brzozów, Gdynia, Kielce, Krakow, Lodz, Lublin
2024-05-30
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Katowice, Kielce, Skorzewo
2024-05-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Bydgoszcz, Warsaw, Bialystok, Gdynia, Poland, Kielce
2024-05-03
Recruiting
Eli Lilly and Company
Phase 3
510
Bialystok, Katowice, Kielce, Krakow, Poznan, Warsaw, Wieliczka, Wroclaw
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Kielce, Krakow, Lodz, Lublin, Piła, Rzeszów, Skierniewice, Tarnów
2024-04-26
Recruiting
Silesian Centre for Heart Diseases
Phase 4
600
Opole, Gliwice, Zabrze, Kielce
2024-04-17
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
Poznan, Bydgoszcz, Warsaw, Koszalin, Kielce
2024-03-28
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Bialystok, Katowice, Kielce, Krakow, Olsztyn, Warsaw, Wroclaw
2024-03-09
Active, closed
Genmab
Phase 3
1,095
Poznan, Krakow, Warsaw, Lodz, Kielce
2024-02-05
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Biała Podlaska, Brzozów, Kielce, Lublin, Szczecin, Wroclaw
2024-01-22
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Kielce
2024-01-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Katowice, Kielce
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Bydgoszcz, Grudziądz, Torun, Siedlce, Koszalin, Szczecin, Kielce
2023-12-31
Recruiting
Eli Lilly and Company
Phase 3
1,264
Kielce, Szczecin, Torun
2023-12-21
Active, closed
Hoffmann-La Roche
Phase 3
1,050
?ód?, Bydgoszcz, Gdynia, Gliwice, Kielce, Konin, Koszalin, Lublin
2023-12-11
Active, closed
Incyte Corporation
Phase 3
450
Gdansk, Gdynia, Katowice, Kielce, Lodz, Skierniewice, Szczecin, Tarnów
2023-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Bydgoszcz, Torun, Warsaw, Przemyśl, Gliwice, Kielce
2023-11-12
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Brzozów, Gda?sk, Katowice, Kielce, Krakow, Wroc?aw
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 2
83
Kielce, Krakow
2023-07-18
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Poznan, Lodz, Lódz, Gdansk, Iława, Bydgoszcz, Katowice, Kielce
2023-07-11
Recruiting
TG Therapeutics, Inc.
Phase 3
800
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw
2023-06-13
Active, closed
Bayer
Phase 3
985
Bydgoszcz, Kielce, Krakow, Lublin, Warsaw, Wroclaw
2023-04-03
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Gdansk, Katowice, Kielce, Lublin
2023-03-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Lublin, Warsaw, Gdansk, Katowice, Olsztyn, Kielce
2023-03-16
Recruiting
Eli Lilly and Company
Phase 3
595
Gdansk, Katowice, Kielce, Krakow, Lodz, Rzeszów, Swietokrzyski, Warsaw
2023-02-27
Active, closed
Genmab
Phase 3
900
Piła, Skórzewo, Słupsk, Olsztyn, Kielce
2023-02-08
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Bialystok, Bydgoszcz, Kalisz, Kielce, Knurów, Krakow, Lodz, Lublin
2023-01-16
Active, closed
AstraZeneca
Phase 3
1,350
Bydgoszcz, Bystra, Grudziądz, Kielce, Koszalin, Olsztyn, Poznan, Przemyśl
2022-12-29
Recruiting
Medical University of Bialystok
Phase 3
160
Bialystok, Kielce
2022-11-01
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Biała Podlaska, Brzozów, Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Poznan
2022-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Brzozów, Gdansk, Katowice, Kielce, Krakow, Lublin, Olsztyn, Szczecin
2022-10-13
Active, closed
Genmab
Phase 3
549
Piła, Skórzewo, Krakow, Gdynia, Kielce
2022-09-20
Active, closed
Biogen
Phase 2/3
450
Kielce, Krakow, Krosno, Lodz, Rzeszów, Warsaw, Wroclaw
2022-09-13
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Krakow, Lublin, Warsaw, Olsztyn, Lodz, Kielce
2022-07-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Poznan, Lublin, Siedlce, Warsaw, Bialystok, Gliwice, Kielce
2022-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Wroclaw, Bydgoszcz, Kielce, Lodz, Lublin, Piotrkow Trybunalski, Poznan, Rzeszów
2021-12-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Poznan, Warsaw, Bialystok, Gdansk, Gliwice, Kielce
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Nowy Targ, Ostrołęka, Sosnowiec, Bialystok, Bydgoszcz, Gdansk, Gdynia, Kielce
2021-11-23
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Gdansk, Katowice, Kielce, Lublin, Warsaw, Wałbrzych, Wroclaw
2021-10-14
Recruiting
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2
32
Bialystok, Gdansk, Gliwice, Kielce
2021-08-26
Recruiting
Valved Graft PMCF Study
NCT04754217Aortic Valve Disease, Ascending Aorta Abnormality, Aortic Dissection
Abbott Medical Devices
Observational
260
Kielce, Krakow, Lodz, Warsaw
2021-07-13
Active, closed
Hoffmann-La Roche
Phase 3
751
Bydgoszcz, Gdansk, Kielce, Krakow, Lodz, Oświęcim, Plewiska, Poznan
2021-03-24
Recruiting
UCB Biopharma SRL
Phase 3
70
Kielce, Krakow, Poznan
2021-03-11
Active, closed
Sellas Life Sciences Group
Phase 3
127
Bydgoszcz, Gdansk, Gdynia, Kielce, Legnica, Olsztyn, Opole, Słomniki
2021-02-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Poznan, Siedlce, Warsaw, Bialystok, Gliwice, Olsztyn, Kielce
2021-01-10
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Gdansk, Kielce, Krakow, Lublin, Olsztyn, Otwock, Poznan, Skorzewo
2020-12-02
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Bydgoszcz, Elblag, Gdansk, Gdynia, Kielce, Koszalin, Lodz, Radom
2020-11-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Gliwice, Kielce
2020-02-11
Recruiting
University Hospital Muenster
Phase 3
683
Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin
2019-08-23
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Bydgoszcz, Gdansk, Glogow Wielkopolski, Katowice, Kielce, Lodz, Poznan, Rzeszów
2018-12-28
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Bialystok, Bydgoszcz, Gdynia, Gliwice, Kielce, Lodz, Olsztyn, Poznan
2015-11-19
Active, closed
AstraZeneca
Phase 3
953
Bydgoszcz, Kielce, Krakow, Lodz, Mrozy, Olsztyn, Poznan, Warsaw
2015-11-03
Active, closed
Genentech, Inc.
Phase 2
378
Gdansk, Kielce, Otwock, Poznan, Rybnik, Warsaw
2008-10-16
Rows per page Showing 1–116 of 116
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/kielce

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 116 of those studies with a site in Kielce.

How many clinical trials are recruiting in Kielce?

64 of the 116 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 50 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kielce), 116 studies
PhaseStudiesRecruitingShare
Phase 3743663.8%
Phase 2221419%
Observational987.8%
Phase 2/3322.6%
Not applicable221.7%
Phase 1201.7%
Phase 1/2211.7%
Phase 4211.7%

Most active sponsors

Lead sponsors with the most studies (Kielce)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC155
AstraZeneca129
Janssen Research & Development, LLC112
Eli Lilly and Company65
Hoffmann-La Roche62
Novartis Pharmaceuticals60
Genmab51
Hospital of the Ministry of Interior, Kielce, Poland32
AbbVie22
Abivax S.A.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.